Work

Pembrolizumab Plus Lenvatinib for Metastatic Renal Cell Carcinoma in a Patient on Hemodialysis

Year: 2025

Type: article

Abstract: Introduction: There is no clear evidence of the safety and efficacy of pembrolizumab plus lenvatinib combination therapy in patients on hemodialysis. This is the first report of a patient on hemodialysis to receive this combination therapy for metastatic renal cell carcinoma. Case Presentation: A 60-year-old man on hemodialysis had cT3bN1M0 unclassified renal cell carcinoma. He received the combination therapy of pembrolizumab plus lenvatinib. Although the dose of lenvatinib was halved to 10 mg/day due to Grade 3 thrombocytopenia, 6 months later, the volumes of the primary lesion and lymph node metastasis were remarkably reduced. Conclusion: Our case report suggests the feasibility of the combination therapy of pembrolizumab plus lenvatinib for patients with metastatic renal cell carcinoma who are undergoing hemodialysis.

Source: IJU Case Reports

DOI: 10.1002/iju5.70011